摘要
目的:探讨恩格列净联合厄贝沙坦治疗糖尿病肾病(DN)肥胖患者的效果及对肾损伤标志物的影响。方法:纳入抚州市医学科学研究所和抚州市立医院2023年5月—2024年5月收治的60例DN肥胖患者,随机分为两组,各30例。对照组予以厄贝沙坦治疗,观察组基于对照组用恩格列净治疗。比较两组治疗前后血糖水平、肾损伤标志物、减重指标及不良反应。结果:治疗后,观察组空腹血糖(FPG)、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)水平均低于对照组,差异均有统计学意义(P<0.05);观察组治疗后24 h尿蛋白定量、血肌酐(Scr)、血尿素氮(BUN)均低于对照组,估计肾小球滤过率(eGFR)水平高于对照组,差异均有统计学意义(P<0.05);观察组治疗后体重轻于对照组,体重指数、腰围、臀围均小于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:恩格列净联合厄贝沙坦治疗DN肥胖患者不仅可以下调血糖水平,还能改善肾功能,有效减轻体重。
Objective:To explore the effect of Empagliflozin combined with Irbesartan in the treatment of obesity patients with diabetic nephropathy(DN)and its influence on kidney injury markers.Method:A total of 60 obesity patients with DN admitted to Fuzhou Medical Science Institute and Fuzhou Municipal Hospital from May 2023 to May 2024 were included and randomly divided into two groups,with 30 cases in each group.The control group was treated with Irbesartan,and the observation group was treated with Empagliflozin on the base of control group.Blood glucose levels,kidney injury markers,weight loss indexes and adverse reactions were compared between the two groups before and after treatment.Result:After treatment,fasting plasma glucose(FPG),glycosylated hemoglobin(HbA1c)and fasting insulin(FINS)levels in observation group were lower than those in control group,the differences were statistically significant(P<0.05).After treatment,24 h urinary protein quantification,serum creatinine(Scr)and blood urea nitrogen(BUN)in observation group were lower than those in control group,and the estimated glomerular filtration rate(eGFR)level was higher than that in control group,the differences were statistically significant(P<0.05).After treatment,the body weight of the observation group was lighter than that of the control group,and the body mass index,waist circumference and hip circumference of observation group were lower than those of control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Empagliflozin combined with Irbesartan in the treatment of obesity patients with DN can not only reduce blood glucose levels,but also improve renal function and effectively reduce weight.
作者
艾丽娟
吴星兴
周盈盈
AI Lijuan;WU Xingxing;ZHOU Yingying(Department of Pharmacy,Fuzhou Medical Science Institute,Fuzhou 344000,China;不详)
出处
《中国医学创新》
2025年第8期59-62,共4页
Medical Innovation of China
基金
抚州市社会发展指导性科技计划项目(抚科社字[2022]9号第54项)。
关键词
糖尿病肾病
肥胖
恩格列净
厄贝沙坦
Diabetic nephropathy
Obesity
Empagliflozin
Irbesartan
作者简介
通信作者:艾丽娟。
